Fresh Equities

Raises

Markets

Learn

Looking for more information?

Contact our responsive and friendly client services team any time.

ASX:IMU logo

ASX:IMU

Imugene Limited

Health Care / Biotechnology

Current price

$0.48

0.015 (3.03%)

Last trade: 26/09, 12:19PM

Market cap

$2.62b

Market closed

Investor Presentations

Principal Activity

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. The company's product pipeline includes oncolytic viruses (subject to share holders approval at the EGM) and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Imugene's oncolytic virus known as CF33, is a chimeric vaccinia derived through a recombination of favourable genetic sequences from multiple pox virus strains to generate a new, safer and more potent virus. The PD-1 B-cell vaccine, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. PD1-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of HER2+ colorectal cancer. Imugene also has two HER2 B-cell vaccines in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both vaccines showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell vaccine technology as well as suggesting therapeutic potential in HER2+ cancers.


Address

Level 3/62 Lygon St, Carlton VIC 3053, Australia

News

Announcements

Filter

All categories
Investor Presentations
Trading Halt
Qtly Cashflow
Issued Capital
Periodic Reports
AnnouncementT+2 MovementDate

Rows per page:

5

0-0 of 0

Market Data

Day

3m

1yr

5yr

Current price

$0.48

Open price

-

Day low-high

-

Price change

-

Percent change

-

Previous close

-

Volume

-

Turnover

-

Bid price

-

Ask price

-

Market cap

-

Shares outstanding

-

Year high

-

Year low

-

Year low-high

-

Earnings per share

-

Price/earnings ratio

-

Dividend yield

-

Dividend per share

-

Franking

-

Investor Presentations

News

Sector Peers

CompanyMarket Cap
Fresh Equities
App Store
Play Store

Copyright © 2021 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9661 0441

clients@freshequities.com

Address

Level 19, 15 William St
Melbourne VIC 3000
Australia

App Store
Play Store

Copyright © 2021 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.